# Apellis Pharmaceuticals, Inc. (APLS) — merger [completed]
Source: sec.gov · situation sit_5b8b6cc9f0d2664ad102 · public 6315666533993186380 · retrieved 2026-08-20T12:59:10.658Z

## Overview
We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

## Key dates
- Announced 2026-04-14 · Completed 2026-05-14

## Timeline
- 2026-04-14 · SC 14D9 (0001193125-26-153887): SC 14D9 - Apellis Pharmaceuticals, Inc. — *We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.* Merger Agreement On March 31, 2026, Biogen, Purchaser and Apellis entered into the merger agreement. The summary of the material provisions of the merger agreement contained in Section 11 ( The Transaction Agreements-The Merger Agreement ) and the description of the conditions to the offer contained in Section 15 ( Conditions to the Offer ) of the offer to purchase are incorporated herein by reference.
  https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-153887.txt
- 2026-05-14 · SC 14D9/A (0001193125-26-222828): SC 14D9/A - Apellis Pharmaceuticals, Inc. — *We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.*
  https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222828.txt

## Citations
- 0001193125-26-153887 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526153887
- 0001193125-26-222828 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526222828